A novel logistic regression model combining semi-supervised learning and active learning for disease classification

Exploring the Value of MRI Measurement of Hippocampal Volume for Predicting the Occurrence and Progression of Alzheimer's Disease Based on Artificial Intelligence Deep Learning Technology and Evidence-Based Medicine Meta-Analysis

BACKGROUND

Alzheimer's disease (AD), a major dementia cause, lacks effective treatment. MRI-based hippocampal volume measurement using artificial intelligence offers new insights into early diagnosis and intervention in AD progression.

OBJECTIVE

This study, involving 483 AD patients, 756 patients with mild cognitive impairment (MCI), and 968 normal controls (NC), investigated the predictive capability of MRI-based hippocampus volume measurements for AD risk using artificial intelligence and evidence-based medicine.

METHODS

Utilizing data from ADNI and OASIS-brains databases, three convolutional neural networks (InceptionResNetv2, Densenet169, and SEResNet50) were employed for automated AD classification based on structural MRI imaging. A multitask deep learning model and a densely connected 3D convolutional network were utilized. Additionally, a systematic meta-analysis explored the value of MRI-based hippocampal volume measurement in predicting AD occurrence and progression, drawing on 23 eligible articles from PubMed and Embase databases.

RESULTS

InceptionResNetv2 outperformed other networks, achieving 99.75% accuracy and 100% AUC for AD-NC classification and 99.16% accuracy and 100% AUC for MCI-NC classification. Notably, at a 512×512 size, InceptionResNetv2 demonstrated a classification accuracy of 94.29% and an AUC of 98% for AD-NC and 97.31% accuracy and 98% AUC for MCI-NC.

CONCLUSIONS

The study concludes that MRI-based hippocampal volume changes effectively predict AD onset and progression, facilitating early intervention and prevention.

A clinician's guide to understanding and critically appraising machine learning studies: a checklist for Ruling Out Bias Using Standard Tools in Machine Learning (ROBUST-ML)

Developing functional machine learning (ML)-based models to address unmet clinical needs requires unique considerations for optimal clinical utility. Recent debates about the rigours, transparency, explainability, and reproducibility of ML models, terms which are defined in this article, have raised concerns about their clinical utility and suitability for integration in current evidence-based practice paradigms. This featured article focuses on increasing the literacy of ML among clinicians by providing them with the knowledge and tools needed to understand and critically appraise clinical studies focused on ML. A checklist is provided for evaluating the rigour and reproducibility of the four ML building blocks: data curation, feature engineering, model development, and clinical deployment. Checklists like this are important for quality assurance and to ensure that ML studies are rigourously and confidently reviewed by clinicians and are guided by domain knowledge of the setting in which the findings will be applied. Bridging the gap between clinicians, healthcare scientists, and ML engineers can address many shortcomings and pitfalls of ML-based solutions and their potential deployment at the bedside.

Image Processing and Machine Learning for Automated Identification of Chemo-/Biomarkers in Chromatography-Mass Spectrometry

We present a method named NPFimg, which automatically identifies multivariate chemo-/biomarker features of analytes in chromatography-mass spectrometry (MS) data by combining image processing and machine learning. NPFimg processes a two-dimensional MS map (m/z vs retention time) to discriminate analytes and identify and visualize the marker features. Our approach allows us to comprehensively characterize the signals in MS data without the conventional peak picking process, which suffers from false peak detections. The feasibility of marker identification is successfully demonstrated in case studies of aroma odor and human breath on gas chromatography-mass spectrometry (GC-MS) even at the parts per billion level. Comparison with the widely used XCMS shows the excellent reliability of NPFimg, in that it has lower error rates of signal acquisition and marker identification. In addition, we show the potential applicability of NPFimg to the untargeted metabolomics of human breath. While this study shows the limited applications, NPFimg is potentially applicable to data processing in diverse metabolomics/chemometrics using GC-MS and liquid chromatography-MS. NPFimg is available as open source on GitHub (http://github.com/poomcj/NPFimg) under the MIT license.

Active semi-supervised learning for biological data classification

Due to datasets have continuously grown, efforts have been performed in the attempt to solve the problem related to the large amount of unlabeled data in disproportion to the scarcity of labeled data. Another important issue is related to the trade-off between the difficulty in obtaining annotations provided by a specialist and the need for a significant amount of annotated data to obtain a robust classifier. In this context, active learning techniques jointly with semi-supervised learning are interesting. A smaller number of more informative samples previously selected (by the active learning strategy) and labeled by a specialist can propagate the labels to a set of unlabeled data (through the semi-supervised one). However, most of the literature works neglect the need for interactive response times that can be required by certain real applications. We propose a more effective and efficient active semi-supervised learning framework, including a new active learning method. An extensive experimental evaluation was performed in the biological context (using the ALL-AML, Escherichia coli and PlantLeaves II datasets), comparing our proposals with state-of-the-art literature works and different supervised (SVM, RF, OPF) and semi-supervised (YATSI-SVM, YATSI-RF and YATSI-OPF) classifiers. From the obtained results, we can observe the benefits of our framework, which allows the classifier to achieve higher accuracies more quickly with a reduced number of annotated samples. Moreover, the selection criterion adopted by our active learning method, based on diversity and uncertainty, enables the prioritization of the most informative boundary samples for the learning process. We obtained a gain of up to 20% against other learning techniques. The active semi-supervised learning approaches presented a better trade-off (accuracies and competitive and viable computational times) when compared with the active supervised learning ones.

Combination of Active Learning and Semi-Supervised Learning under a Self-Training Scheme

One of the major aspects affecting the performance of the classification algorithms is the amount of labeled data which is available during the training phase. It is widely accepted that the labeling procedure of vast amounts of data is both expensive and time-consuming since it requires the employment of human expertise. For a wide variety of scientific fields, unlabeled examples are easy to collect but hard to handle in a useful manner, thus improving the contained information for a subject dataset. In this context, a variety of learning methods have been studied in the literature aiming to efficiently utilize the vast amounts of unlabeled data during the learning process. The most common approaches tackle problems of this kind by individually applying active learning or semi-supervised learning methods. In this work, a combination of active learning and semi-supervised learning methods is proposed, under a common self-training scheme, in order to efficiently utilize the available unlabeled data. The effective and robust metrics of the entropy and the distribution of probabilities of the unlabeled set, to select the most sufficient unlabeled examples for the augmentation of the initial labeled set, are used. The superiority of the proposed scheme is validated by comparing it against the base approaches of supervised, semi-supervised, and active learning in the wide range of fifty-five benchmark datasets.

Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery

Artificial intelligence (AI), and, in particular, deep learning as a subcategory of AI, provides opportunities for the discovery and development of innovative drugs. Various machine learning approaches have recently (re)emerged, some of which may be considered instances of domain-specific AI which have been successfully employed for drug discovery and design. This review provides a comprehensive portrayal of these machine learning techniques and of their applications in medicinal chemistry. After introducing the basic principles, alongside some application notes, of the various machine learning algorithms, the current state-of-the art of AI-assisted pharmaceutical discovery is discussed, including applications in structure- and ligand-based virtual screening, de novo drug design, physicochemical and pharmacokinetic property prediction, drug repurposing, and related aspects. Finally, several challenges and limitations of the current methods are summarized, with a view to potential future directions for AI-assisted drug discovery and design.